ME03437B - Muteini interleukina-2 za ekspanziju t-regulatornih ćelija - Google Patents

Muteini interleukina-2 za ekspanziju t-regulatornih ćelija

Info

Publication number
ME03437B
ME03437B MEP-2019-162A MEP2019162A ME03437B ME 03437 B ME03437 B ME 03437B ME P2019162 A MEP2019162 A ME P2019162A ME 03437 B ME03437 B ME 03437B
Authority
ME
Montenegro
Prior art keywords
leu
thr
ser
lys
glu
Prior art date
Application number
MEP-2019-162A
Other languages
German (de)
English (en)
French (fr)
Inventor
Marc A Gavin
Gunasekaran Kannan
Li Li
Joshua T Pearson
Margaret Karow
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of ME03437B publication Critical patent/ME03437B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

LISTA SEKVENCI
[0223]
<110> AMGEN INC.
<120> MUTEINI INTERLEUKINA-2 ZA EKSPANZIJU T-REGULATORNIH ĆELIJA
<130> A-1826-WO-PCT
<140>
<141>
<150> 61/784,669
<151> 2013-03-14
<160> 38
<170> PatentIn verzija 3.5
<210> 1
<211> 133
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski polipeptid
<220>
<221> MOD_RES
<222> (125)..(125)
<223> Cys, Ser, Val ili Ala
<400> 1
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Lys Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Xaa Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 2
<211> 133
<212> PRT
<213> Homo sapiens
<220>
<221> MOD_RES
<222> (125)..(125)
<223> Cys, Ser, Val ili Ala
<400> 2
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Xaa Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 3
<211> 227
<212> PRT
<213> Homo sapiens
<400> 3
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly Lys
225
<210> 4
<211> 226
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski polipeptid
<400> 4
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly
225
<210> 5
<211> 5
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski peptid
<400> 5
Gly Gly Gly Gly Ser
1 5
<210> 6
<211> 5
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski peptid
<400> 6
Gly Gly Asn Gly Thr
1 5
<210> 7
<211> 5
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski peptid
<400> 7
Tyr Gly Asn Gly Thr
1 5
<210> 8
<211> 133
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski polipeptid
<400> 8
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Ala Leu Asn Leu Ala Pro Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asp Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ala Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 9
<211> 133
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski polipeptid
<400> 9
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Ser Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Ala Leu Asn Leu Ala Pro Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asp Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ala Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 10
<211> 133
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski polipeptid
<400> 10
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Arg Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Ala Leu Asn Leu Ala Pro Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asp Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ala Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 11
<211> 133
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski polipeptid
<400> 11
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Ala Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Ala Leu Asn Leu Ala Pro Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asp Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ala Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 12
<211> 133
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski polipeptid
<400> 12
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Glu
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Ala Leu Asn Leu Ala Pro Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asp Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ala Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 13
<211> 133
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski polipeptid
<400> 13
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Asp Ala Leu Asn Leu Ala Pro Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asp Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ala Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 14
<211> 133
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski polipeptid
<400> 14
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Ala Leu Arg Leu Ala Pro Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asp Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ala Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 15
<211> 133
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski polipeptid
<400> 15
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Arg Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Glu
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Asp Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asp Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ala Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 16
<211> 364
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski polipeptid
<400> 16
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly Gly Gly Gly Gly Ser Ala Pro Thr Ser Ser Ser Thr Lys Lys
225 230 235 240
Thr Gln Leu Gln Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu
245 250 255
Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr
260 265 270
Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln
275 280 285
Cys Leu Glu Glu Glu Leu Lys Pro Leu Glu Glu Val Leu Asn Leu Ala
290 295 300
Gln Ser Lys Asn Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile
305 310 315 320
Asn Val Ile Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys
325 330 335
Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp
340 345 350
Ile Thr Phe Ala Gln Ser Ile Ile Ser Thr Leu Thr
355 360
<210> 17
<211> 364
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski polipeptid
<400> 17
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly Gly Gly Gly Gly Ser Ala Pro Thr Ser Ser Ser Thr Lys Lys
225 230 235 240
Thr Gln Leu Gln Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu
245 250 255
Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr
260 265 270
Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln
275 280 285
Cys Leu Glu Glu Glu Leu Lys Pro Leu Glu Glu Ala Leu Asn Leu Ala
290 295 300
Pro Ser Lys Asn Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile
305 310 315 320
Asn Lys Ile Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys
325 330 335
Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp
340 345 350
Ile Thr Phe Ala Gln Ser Ile Ile Ser Thr Leu Thr
355 360
<210> 18
<211> 364
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski polipeptid
<400> 18
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly Gly Gly Gly Gly Ser Ala Pro Thr Ser Ser Ser Thr Lys Lys
225 230 235 240
Thr Gln Leu Gln Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu
245 250 255
Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr
260 265 270
Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln
275 280 285
Cys Leu Glu Glu Glu Leu Lys Pro Leu Glu Glu Val Leu Asn Leu Ala
290 295 300
Gln Ser Lys Asn Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile
305 310 315 320
Asn Lys Ile Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys
325 330 335
Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp
340 345 350
Ile Thr Phe Ala Gln Ser Ile Ile Ser Thr Leu Thr
355 360
<210> 19
<211> 364
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski polipeptid
<400> 19
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly Gly Gly Gly Gly Ser Ala Pro Thr Ser Ser Ser Thr Lys Lys
225 230 235 240
Thr Gln Leu Gln Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu
245 250 255
Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr
260 265 270
Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln
275 280 285
Cys Leu Glu Glu Glu Leu Lys Pro Leu Glu Glu Ala Leu Asn Leu Ala
290 295 300
Pro Ser Lys Asn Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asp Ile
305 310 315 320
Asn Val Ile Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys
325 330 335
Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp
340 345 350
Ile Thr Phe Ala Gln Ser Ile Ile Ser Thr Leu Thr
355 360
<210> 20
<211> 364
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski polipeptid
<400> 20
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gly Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly Gly Gly Gly Gly Ser Ala Pro Thr Ser Ser Ser Thr Lys Lys
225 230 235 240
Thr Gln Leu Gln Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu
245 250 255
Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr
260 265 270
Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln
275 280 285
Cys Leu Glu Glu Glu Leu Lys Pro Leu Glu Glu Val Leu Asn Leu Ala
290 295 300
Gln Ser Lys Asn Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asp Ile
305 310 315 320
Asn Val Ile Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys
325 330 335
Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp
340 345 350
Ile Thr Phe Ala Gln Ser Ile Ile Ser Thr Leu Thr
355 360
<210> 21
<211> 6
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetska oznaka 6xHis
<400> 21
His His His His His His
1 5
<210> 22
<211> 42
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski polipeptid
<400> 22
Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser
1 5 10 15
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
20 25 30
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn
35 40
<210> 23
<211> 30
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski polipeptid
<400> 23
Thr Gln Lys Ser Leu Ser Leu Ser Ser Ser Thr Lys Lys Thr Gln Leu
1 5 10 15
Gln Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu Asn
20 25 30
<210> 24
<211> 29
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski peptid
<400> 24
Thr Gln Lys Ser Leu Ser Leu Ser Ser Thr Lys Lys Thr Gln Leu Gln
1 5 10 15
Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu Asn
20 25
<210> 25
<211> 28
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski peptid
<400> 25
Thr Gln Lys Ser Leu Ser Leu Ser Thr Lys Lys Thr Gln Leu Gln Leu
1 5 10 15
Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu Asn
20 25
<210> 26
<211> 27
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski peptid
<400> 26
Thr Gln Lys Ser Leu Ser Leu Ser Lys Lys Thr Gln Leu Gln Leu Glu
1 5 10 15
His Leu Leu Leu Asp Leu Gln Met Ile Leu Asn
20 25
<210> 27
<211> 26
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski peptid
<400> 27
Thr Gln Lys Ser Leu Ser Leu Ser Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn
20 25
<210> 28
<211> 25
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski peptid
<400> 28
Thr Gln Lys Ser Leu Ser Leu Ser Thr Gln Leu Gln Leu Glu His Leu
1 5 10 15
Leu Leu Asp Leu Gln Met Ile Leu Asn
20 25
<210> 29
<211> 24
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski peptid
<400> 29
Thr Gln Lys Ser Leu Ser Leu Ser Gln Leu Gln Leu Glu His Leu Leu
1 5 10 15
Leu Asp Leu Gln Met Ile Leu Asn
20
<210> 30
<211> 23
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski peptid
<400> 30
Thr Gln Lys Ser Leu Ser Leu Gln Leu Gln Leu Glu His Leu Leu Leu
1 5 10 15
Asp Leu Gln Met Ile Leu Asn
20
<210> 31
<211> 29
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski peptid
<400> 31
Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser
1 5 10 15
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln
20 25
<210> 32
<211> 28
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski peptid
<400> 32
Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser Ala
1 5 10 15
Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln
20 25
<210> 33
<211> 24
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski peptid
<400> 33
Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Ala Ala Pro Thr Ser Ser
1 5 10 15
Ser Thr Lys Lys Thr Gln Leu Gln
20
<210> 34
<211> 24
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski peptid
<400> 34
Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Ala Ala Pro Ala Ser Ser
1 5 10 15
Ser Thr Lys Lys Thr Gln Leu Gln
20
<210> 35
<211> 28
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski peptid
<400> 35
Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser Ala
1 5 10 15
Pro Asn Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln
20 25
<210> 36
<211> 28
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski peptid
<400> 36
Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser Ala
1 5 10 15
Pro Asn Ser Thr Ser Thr Lys Lys Thr Gln Leu Gln
20 25
<210> 37
<211> 28
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski peptid
<400> 37
Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Asn Gly Thr Ala
1 5 10 15
Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln
20 25
<210> 38
<211> 28
<212> PRT
<213> Veštačka sekvenca
<220>
<223> Opis veštačke sekvence: sintetski peptid
<400> 38
Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Tyr Gly Asn Gly Thr Ala
1 5 10 15
Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln
20 25

Claims (13)

  1. l. Fc-fuzioni protein koji sadrži Fc i mutein humanog interleukina-2 (IL-2) koji sadrži V91K supstituciju i aminokiselinsku sekvencu najmanje 90% identičnu sa aminokiselinskom sekvencom navedenom u SEQ ID NO:l, pri čemu navedeni IL-2 mutein stimuliše T regulatorne ćelije.
  2. 2. Fc-fuzioni protein prema patentnom zahtevu l, naznačen time što Fc je Fc humanog IgG l ili Fc humanog IgG l koji sadrži jednu ili više mutacija koje menjaju efektomu funkciju navedenog Fc kao što je supstitucija na N297 i/ili supstitucija ili delecija e-terminalnog lizina navedenog Fc humanog IgG.
  3. 3. Fc-fuzioni protein prema patentnom zahtevu l ili 2, naznačen time što linker povezuje delove Fc i mutein humanog IL-2 navedenog proteina kao što je GGGGS (SEQ ID NO: 5), GGNGT (SEQ ID N0:6) ili YGNGT (SEQ ID N0:7).
  4. 4. Fc-fuzioni protein prema bilo kom od patentnih zahteva l do 3, naznačen time što mutein IL-2 dalje sadrži aminokiselinsku adiciju, supstituciju ili deleciju koja menja glikozilaciju navedenog Fc fuzionog proteina kada je eksprimiran u sisarskim ćelijama.
  5. 5. Fc-fuzioni protein prema bilo kom od patentnih zahteva l do 4, naznačen time što navedeni Fc fuzioni protein sadrži Fc dimer dva muteina IL-2 ili jednog muteina IL-2.
  6. 6. Fc fuzioni protein prema patentnom zahtevu l, koji ima sekvencu prema SEQ ID NO:18.
  7. 7. Izolovana nukleinska kiselina koja kodira Fc-fuzioni protein prema patentnim zahtevima l do 6.
  8. 8. Izolovana nukleinska kiselina prema patentnom zahtevu 7, naznačena time što Fc je Fc humanog IgGl.
  9. 9. Ekspresioni vektor koji sadrži izolovanu nukleinsku kiselinu prema patentnom zahtevu 7 ili patentnom zahtevu 8, operativno vezan za promotor.
  10. 10. Ćelija domaćin koja sadrži izolovanu nukleinsku kiselinu prema patentnom zahtevu 7 ili patentnom zahtevu 8 naznačena time što navedena ćelija domaćin je prokariotska ćelija kao što je E. coli ili eukariotska ćelija kao što je sisarska ćelija uključujući, ali bez ograničenja na ćelijsku liniju jajnika kineskog hrčka (CHO).
  11. ll. Postupak za pripremu Fc-fuzionog proteina prema bilo kom od patentnih zahteva l do 6 koji sadrži kultivaciju ćelije domaćina prema patentnom zahtevu l O i sakupljanje Fc-fuzionog proteina iz navedene kulture.
  12. 12. Mutein humanog IL-2 koji sadrži V91K supstituciju i aminokiselinsku sekvencu najmanje 90% identičnu sa aminokiselinskom sekvencom navedenom u SEQ ID NO:l ili Fc-fuzioni protein prema bilo kom od patentnih zahteva l do 6 za upotrebu u in vivo postupku za lečenje subjekta sa inflamatornom ili autoimunom bolešću.
  13. 13. Mutein IL-2 prema patentnom zahtevu l ili Fc-fuzioni protein prema bilo kom od patentnih zahteva l do 6 za upotrebu prema patentnom zahtevu 12, naznačen time što bolest je atopijska bolest, paraneoplastična autoimuna bolest, inflamacija hrskavice, artritis, reumatoidni artritis, juvenilni artritis, juvenilni reumatoidni artritis, pauciartikularni juvenilni reumatoidni artritis, poliartikularni juvenilni reumatoidni artritis, juvenilni reumatoidni artritis sa sistemskim početkom, juvenilni ankilozni spondilitis, juvenilni enteropatski artritis, juvenilni reaktivni artritis, juvenilni Reiter-ov sindrom, SEA sindrom (sindrom seronegativnosti, entezopatije, artropatije), juvenilni dermatomiozitis, juvenilni psorijatički artritis, juvenilna skleroderma, juvenilni sistemski lupus eritematozus, juvenilni vaskulitis, pauciartikularni reumatoidni artritis, poliartikularni reumatoidni artritis, reumatoidni artritis sa sistemskim početkom, ankilozni spondilitis, enteropatski artritis, reaktivni artritis, Reiter-ov sindrom, SEA sindrom (sindrom seronegativnosti, entezopatije, artropatije), dermatomiozitis, psorijatički artritis, skleroderma, vaskulitis, miolitis, polimiolitis, dermatomiolitis, poliarteritis nodoza, Wegener-ov granulomatozis, arteritis, polimijalgija reumatika, sarkoidoza, skleroderma, primarna bilijarna skleroza, sklerotizujući holangitis, Sjogren-ov sindrom, psorijaza, psorijaza sa plakovima, kapljična psorijaza, inverzna psorijaza, pustularna psorijaza, eritrodermna psorijaza, dermatitis, atopijski dermatitis, ateroskleroza, lupus, Still-ova bolest, sistemski lupus eritematozus (SLE), mijastenija gravis, vaskulitis indukovan hepatitisom C, dijabetes melitus tipa l, multipla skleroza, spontani gubitak trudnoće, atopijske bolesti, ili inflamatome bolesti creva, Crohn-ova bolest, ulcerozni kolitis, celijačna bolest, astma, COPD, rinosinuzitis, rinosinuzitis sa polipima, eozinofilni ezofagitis, eozinofilni bronhitis, Guillain-Barre ova bolest, tiroiditis (npr., Graves-ova bolest), Addison-ova bolest, Raynaud-ov fenomen, autoimuni hepatitis, bolest transplanta protiv domaćina, odbacivanje transplanta ili oštećenje bubrega.
MEP-2019-162A 2013-03-14 2014-03-14 Muteini interleukina-2 za ekspanziju t-regulatornih ćelija ME03437B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784669P 2013-03-14 2013-03-14
PCT/US2014/029111 WO2014153111A2 (en) 2013-03-14 2014-03-14 Interleukin-2 muteins for the expansion of t-regulatory cells
EP14722463.8A EP2970423B1 (en) 2013-03-14 2014-03-14 Interleukin-2 muteins for the expansion of t-regulatory cells

Publications (1)

Publication Number Publication Date
ME03437B true ME03437B (me) 2020-01-20

Family

ID=50680166

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2019-162A ME03437B (me) 2013-03-14 2014-03-14 Muteini interleukina-2 za ekspanziju t-regulatornih ćelija
MEP-2019-148A ME03482B (me) 2013-03-14 2014-03-14 POLIPETPIDI KOJI SADRŽE NEGLIKOZILISANI Fc

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2019-148A ME03482B (me) 2013-03-14 2014-03-14 POLIPETPIDI KOJI SADRŽE NEGLIKOZILISANI Fc

Country Status (40)

Country Link
US (8) US9546203B2 (me)
EP (2) EP2970441B1 (me)
JP (6) JP6480409B2 (me)
KR (5) KR20250002742A (me)
CN (2) CN105143253B (me)
AP (1) AP2015008737A0 (me)
AR (1) AR095541A1 (me)
AU (2) AU2014236281B2 (me)
BR (1) BR112015022440B1 (me)
CA (3) CA2906708C (me)
CL (2) CL2015002669A1 (me)
CR (2) CR20200004A (me)
CY (2) CY1121767T1 (me)
DK (2) DK2970441T3 (me)
EA (2) EA032863B1 (me)
ES (2) ES2720225T3 (me)
HR (2) HRP20190970T1 (me)
HU (2) HUE043488T2 (me)
IL (2) IL241349B (me)
JO (1) JO3796B1 (me)
LT (2) LT2970441T (me)
MA (2) MA38477B1 (me)
ME (2) ME03437B (me)
MX (2) MX366854B (me)
MY (2) MY172991A (me)
NZ (1) NZ751148A (me)
PE (1) PE20151763A1 (me)
PH (1) PH12015502051B1 (me)
PL (2) PL2970423T3 (me)
PT (2) PT2970441T (me)
RS (2) RS58854B1 (me)
SG (2) SG11201507420UA (me)
SI (2) SI2970423T1 (me)
SM (2) SMT201900415T1 (me)
TN (1) TN2015000416A1 (me)
TR (2) TR201908362T4 (me)
TW (3) TWI687435B (me)
UA (1) UA119140C2 (me)
UY (2) UY40090A (me)
WO (2) WO2014153111A2 (me)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20190202898A9 (en) * 2012-04-03 2019-07-04 Novelmed Therapeutics, Inc. AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
EP2904014A4 (en) * 2012-10-04 2016-09-28 Novelmed Therapeutics Inc FOR ALTERNATIVE PATHS, SPECIFIC ANTIBODIES FOR THE TREATMENT OF HEMOLYTIC DISEASES
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
CN105143267B (zh) 2013-03-15 2020-06-26 美国安进公司 人pac1抗体
RS57393B1 (sr) 2013-03-15 2018-09-28 Hoffmann La Roche Il-22 polipeptiidi i il-22 fuzioni proteini i metode za njihovu upotrebu
SI3102595T1 (sl) 2014-02-06 2019-02-28 F. Hoffmann-La Roche Ag Fuzijske beljakovine z interlevkinom-2 in njihova uporaba
KR102493543B1 (ko) 2014-07-21 2023-01-30 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
PL3482766T3 (pl) 2014-08-11 2020-11-16 Delinia, Inc. Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych
AU2015318008B2 (en) 2014-09-15 2021-05-20 Amgen Inc. Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
PT3233192T (pt) * 2014-12-15 2021-07-19 Univ Washington Composições e métodos para entrega visada de citocinas
MX2017012966A (es) 2015-04-10 2018-06-06 Amgen Inc Muteinas de interleuquina 2 para la expansion de celulas t regulatorias.
CA2982362A1 (en) * 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EP3353288A1 (en) 2015-09-22 2018-08-01 H. Hoffnabb-La Roche Ag Expression of fc-containing proteins
EP3390447A1 (en) 2015-12-15 2018-10-24 Amgen Inc. Pacap antibodies and uses thereof
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
LT3411404T (lt) * 2016-02-03 2022-12-27 Amgen Research (Munich) Gmbh Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai
SG11201805770UA (en) * 2016-02-03 2018-08-30 Amgen Res Munich Gmbh BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
JP7220458B2 (ja) 2016-02-05 2023-02-10 ワシントン・ユニバーシティ 標的サイトカインデリバリーのための組成物および方法
CN107287273B (zh) * 2016-03-31 2021-03-09 复旦大学附属妇产科医院 表达Tim-3的外周血NK细胞在制备自然流产生物标记物中的用途
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
KR20250133490A (ko) * 2016-05-04 2025-09-05 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
ES2988783T3 (es) 2016-06-22 2024-11-21 David Klatzmann Linfocitos T genéticamente modificados
WO2018027025A1 (en) * 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
KR101928981B1 (ko) * 2016-09-02 2018-12-13 고려대학교 산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
EA201991142A1 (ru) 2016-11-08 2019-10-31 Варианты il-2 для лечения аутоиммунных заболеваний
WO2018106885A1 (en) 2016-12-07 2018-06-14 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
JP2020521452A (ja) * 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
MA50619A (fr) 2017-10-04 2020-08-12 Amgen Inc Fusions d'immunoglobulines de transthyrétine
EP3713592A4 (en) 2017-11-21 2022-01-12 The Board of Trustees of the Leland Stanford Junior University INTERLEUKIN-2 PARTIAL AGONISTS
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2019112854A1 (en) * 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Il-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3720871A4 (en) * 2017-12-06 2021-09-15 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
MA51291A (fr) 2017-12-19 2020-10-28 Xencor Inc Protéines de fusion il-2 fc modifiées
WO2019131964A1 (ja) * 2017-12-27 2019-07-04 協和発酵キリン株式会社 Ｉｌ－２改変体
EP3737699A1 (en) * 2018-01-12 2020-11-18 Amgen Inc. Pac1 antibodies and uses thereof
NZ766453A (en) 2018-02-01 2022-02-25 Nkmax Co Ltd Method of producing natural killer cells and composition for treating cancer
WO2019158764A1 (en) 2018-02-16 2019-08-22 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
US11359000B2 (en) * 2018-03-28 2022-06-14 Bristol-Myers Squibb Company Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
US12048296B2 (en) 2018-06-07 2024-07-30 Korea Research Institute Of Bioscience And Biotechnology Transgenic mouse for aglycosylated antibody production and use of aglycosylated antibody produced therefrom
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CN112638406B (zh) 2018-06-22 2025-04-22 科优基因公司 白介素-2变体及其使用方法
CN112654633B (zh) 2018-06-22 2025-05-09 科优基因公司 基于细胞因子的可生物活化药物及其使用方法
UY38289A (es) 2018-07-02 2020-01-31 Amgen Inc Proteína de unión al antígeno anti-steap1
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2020088164A1 (zh) 2018-11-01 2020-05-07 山东新时代药业有限公司 双特异性抗体及其用途
EP3920899A2 (en) 2019-02-08 2021-12-15 The UAB Research Foundation Immunotherapy for the treatment and prevention of inflammatory bowel disease
CA3129317A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
KR20210128443A (ko) 2019-02-15 2021-10-26 인테그럴 몰큘러 인코포레이티드 클라우딘 6 항체 및 이의 용도
AU2020252119B2 (en) * 2019-03-29 2025-09-04 Centre National De La Recherche Scientifique - Cnrs Interleukin-2 variants with modified biological activity
CN111944036B (zh) * 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
EP3980051A4 (en) * 2019-06-05 2023-09-13 Asher Biotherapeutics, Inc. FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS
AU2020289474A1 (en) 2019-06-07 2021-12-23 Amgen Inc. Bispecific binding constructs
SG11202112762TA (en) 2019-07-08 2021-12-30 Amgen Inc Multispecific transthyretin immunoglobulin fusions
KR20220051177A (ko) * 2019-07-26 2022-04-26 비스테라, 인크. 인터류킨-2 작용제 및 이의 용도
US20220306714A1 (en) * 2019-08-12 2022-09-29 AskGene Pharma, Inc. Il-2 fusion proteins that preferentially bind il-2ralpha
AU2020328038B2 (en) * 2019-08-13 2025-10-09 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
WO2021049606A1 (ja) 2019-09-13 2021-03-18 協和キリン株式会社 ＤｃＲ３改変体
WO2021066869A1 (en) 2019-10-04 2021-04-08 TAE Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
CN114829585B (zh) * 2019-11-20 2024-08-23 吉爱希公司 用于培养t细胞的组合物及使用其来培养t细胞的方法
CN114929249A (zh) * 2019-11-29 2022-08-19 Nkmax有限公司 产生自然杀伤细胞及其组合物的方法
CN115190885A (zh) 2019-12-12 2022-10-14 艾尔图制药公司 白细胞介素2嵌合构建体
IL293471A (en) 2019-12-17 2022-08-01 Amgen Inc Dual interleukin-2 / tnf receptor agonist for use in medicine
WO2021127495A1 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
EP4122951A4 (en) * 2020-03-19 2024-05-29 Innovent Biologics (Singapore) Pte. Ltd. INTERLEUKIN-2 MUTANT AND USE THEREOF
US20230145766A1 (en) * 2020-03-19 2023-05-11 Innovent Biologics (Suzhou) Co., Ltd. Interleukin-2 mutant and use thereof
WO2021207074A2 (en) * 2020-04-06 2021-10-14 Lung Biotechnology Pbc Modular synthetic receptors and methods of use
IL298136A (en) 2020-05-13 2023-01-01 Bonum Therapeutics Inc Preparations of protein complexes and methods of using them
US20230203198A1 (en) 2020-06-04 2023-06-29 Amgen Inc. Bispecific binding constructs
US20230226203A1 (en) * 2020-06-18 2023-07-20 Proviva Therapeutics (Hong Kong) Limited Activatable procytokines
CN112048018B (zh) * 2020-08-31 2021-10-08 南方医科大学 一种嵌合t细胞生长因子及其应用
CN116323653A (zh) 2020-09-04 2023-06-23 山东先声生物制药有限公司 Il-2突变体及其应用
MX2023005030A (es) 2020-10-29 2023-05-16 Bristol Myers Squibb Co Proteinas de fusion para el tratamiento de enfermedades.
KR20230117397A (ko) 2020-12-03 2023-08-08 암젠 인크 다중 결합 도메인을 갖는 분자
KR20230129018A (ko) * 2020-12-04 2023-09-05 비스테라, 인크. 인터류킨-2 작용제를 사용하는 방법
KR20250007039A (ko) * 2020-12-23 2025-01-13 머크 샤프 앤드 돔 엘엘씨 자가면역 및 염증성 질환을 치료하기 위한 il-2 뮤테인
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
KR20240024829A (ko) 2021-05-19 2024-02-26 애셔 바이오테라퓨틱스, 인크. Il-21 폴리펩타이드 및 표적화된 작제물
US12297273B2 (en) 2021-05-27 2025-05-13 Sanofi Fc variant with enhanced affinity to Fc receptors and improved thermal stability
WO2023288283A2 (en) 2021-07-14 2023-01-19 Synthekine, Inc. Methods and compositions for use in cell therapy of neoplastic disease
WO2023015298A1 (en) * 2021-08-06 2023-02-09 Amgen Inc. Isolation of therapeutic protein
MX2024004291A (es) 2021-10-06 2024-06-28 Iltoo Pharma Construcciones quiméricas de interleucina 2 con especificidad de direccionamiento a tejidos inflamados.
KR20240099272A (ko) 2021-10-14 2024-06-28 테네오바이오, 인코포레이티드 메소텔린 결합 단백질 및 이의 용도
JP2024539749A (ja) * 2021-10-14 2024-10-29 ラッティコン （スージョウ） バイオファーマシューティカルズ カンパニー リミテッド 新規な抗体－サイトカイン融合タンパク質及びその製造方法と使用
JP2024543209A (ja) * 2021-12-01 2024-11-19 ビステラ， インコーポレイテッド インターロイキン－２剤の使用方法
WO2023148397A1 (en) 2022-02-07 2023-08-10 Vib Vzw Engineered stabilizing aglycosylated fc-regions
EP4482511A2 (en) * 2022-02-22 2025-01-01 The Regents of The University of Michigan Compositions and methods for treating autoimmune disorders
JP2025508979A (ja) * 2022-03-03 2025-04-10 ハイナン シンセア ファーマスーティカル カンパニー、リミテッド ＩＬ２変異体－抗体Ｆｃブロック融合タンパク質の医薬組成物及びその使用
US20250215452A1 (en) 2022-03-25 2025-07-03 Universität Zürich Adenoviral Mediated Targeting of Activated Immune Cells
AU2023274452A1 (en) 2022-05-27 2025-01-16 Innate Pharma Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
EP4561613A1 (en) 2022-07-27 2025-06-04 Teneobio, Inc. Mesothelin binding proteins and uses thereof
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder
EP4598958A1 (en) 2022-10-05 2025-08-13 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
AR130869A1 (es) 2022-10-25 2025-01-29 Ablynx Nv Polipéptidos de variantes de fc diseñados por glicoingeniería con función efectora aumentada
CN120282987A (zh) 2022-11-30 2025-07-08 因特格尔莫来库乐有限公司 包括双特异性型式的针对紧密连接蛋白6的抗体
CN120529914A (zh) 2023-01-09 2025-08-22 奥德赛治疗股份有限公司 抗tnfr2抗原结合蛋白及其用途
AU2024226156A1 (en) 2023-02-21 2025-08-28 Teneobio, Inc. C-kit binding proteins, chimeric antigen receptors, and uses thereof
AR133427A1 (es) 2023-07-31 2025-09-24 Sanofi Sa Anticuerpos anti-gprc5d y composiciones
WO2025049858A1 (en) 2023-09-01 2025-03-06 Amgen Inc. Molecules for treatment of cancer
WO2025096843A1 (en) 2023-11-03 2025-05-08 Amgen Inc. Bispecific molecules
WO2025096842A2 (en) 2023-11-03 2025-05-08 Amgen Inc. Fibroblast targeting molecules
WO2025106529A2 (en) * 2023-11-14 2025-05-22 Cavalry Biosciences, Inc. Compositions for targeting muscle cells and uses thereof
WO2025133290A1 (en) 2023-12-21 2025-06-26 Temper Bio Protein for immune regulation
WO2025149633A1 (en) 2024-01-12 2025-07-17 Laigo Bio B.V. Bispecific antigen binding proteins
US20250313641A1 (en) 2024-04-09 2025-10-09 Amgen Inc. Agonistic anti-il-2rbg heavy-chain antibodies
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2025221954A1 (en) 2024-04-17 2025-10-23 Visterra, Inc. Use of il-2 variant for treating kidney transplant rejection
WO2025259515A2 (en) 2024-06-11 2025-12-18 Amgen Inc. Combination treatment

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233A (en) 1837-06-14 Improvement in plows
US4447A (en) 1846-04-04 Car- wheel
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0351410A1 (en) 1987-03-18 1990-01-24 3i RESEARCH EXPLOITATION LIMITED Complement-binding peptide
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
CA2062582C (en) 1991-03-27 1996-03-26 Tse-Wen Chang Methods and substances for recruiting therapeutic agents to solid tissues
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6037525A (en) 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
FR2752462B1 (fr) 1996-08-14 1998-10-23 Essilor Int Procede d'incorporation d'additifs dans un article ophtalmique au moyen d'un fluide a l'etat supercritique
US6245974B1 (en) 1997-08-06 2001-06-12 North Carolina State University Matrix attachment regions
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6177612B1 (en) 1998-07-31 2001-01-23 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada Matrix attachment regions
US6388066B1 (en) 1998-09-29 2002-05-14 Pioneer Hi-Bred International, Inc. MAR/SAR elements flanking RSYN7-driven construct
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
MXPA03005036A (es) * 2000-12-07 2003-09-05 Lilly Co Eli Proteinas de fusion glp-1.
WO2002048379A1 (en) 2000-12-15 2002-06-20 Pangen Biotech Inc. Expression vector for animal cell containing nuclear matrix attachment region fo interferon beta
EP1395669B1 (en) 2001-01-26 2009-07-22 Selexis S.A. Matrix attachment regions and methods for use thereof
EP2354791A1 (en) 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ATE525395T1 (de) 2003-06-12 2011-10-15 Lilly Co Eli Fusions proteine von glp-1-analoga
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
CA2545755A1 (en) 2003-11-12 2005-05-26 Schering Corporation Plasmid system for multigene expression
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
CA2557677A1 (en) 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
CA2606809C (en) * 2005-05-06 2016-01-05 Providence Health System Trimeric ox40-immunoglobulin fusion protein and methods of use
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
US20070036786A1 (en) * 2005-07-11 2007-02-15 Nadine Tuaillon Method of treating autoimmune disease using humanized anti-CD16A antibodies
WO2008112325A2 (en) 2007-03-15 2008-09-18 Biogen Idec Ma Inc. Treatment of autoimmune disorders
GB0623539D0 (en) 2006-11-24 2007-01-03 Avidex Ltd Polypeptides
US20090016935A1 (en) 2007-07-09 2009-01-15 Andrianov Alexander K Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
US20110274650A1 (en) 2009-01-21 2011-11-10 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
CA2750533A1 (en) * 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
JP2013511281A (ja) 2009-11-23 2013-04-04 アムジェン インコーポレイテッド 単量体抗体Ｆｃ
WO2011076781A1 (en) * 2009-12-22 2011-06-30 Novartis Ag Tetravalent cd47-antibody constant region fusion protein for use in therapy
BR112013013083A2 (pt) 2010-11-30 2016-12-13 Genentech Inc métodos para transportar um composto, para aumentar exposição do cns a um composto, para diminuir a depuração de um composto, para aumentar a retenção no cns de um composto, para otimizar a farmacocinética, para tratar um distúrbio neurológico em um mamífero, para desenvolver um anticorpo, anticorpo, fragmento de anticorpo, anticorpo multiespecífico e uso de um anticorpo
CN105440123B (zh) * 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
JP5972915B2 (ja) 2011-03-16 2016-08-17 アムジエン・インコーポレーテツド Ｆｃ変異体
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA3111357A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
CN104093740B (zh) 2012-02-06 2018-01-09 弗·哈夫曼-拉罗切有限公司 使用csf1r抑制剂的组合物和方法
KR102031317B1 (ko) 2012-05-21 2019-10-14 제넨테크, 인크. 혈액-뇌 장벽 수송의 안전성을 개선하는 방법
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
RS57393B1 (sr) * 2013-03-15 2018-09-28 Hoffmann La Roche Il-22 polipeptiidi i il-22 fuzioni proteini i metode za njihovu upotrebu
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
CN105358570A (zh) 2016-02-24
HUE043488T2 (hu) 2019-08-28
AU2014236281A1 (en) 2015-09-24
CA3149348A1 (en) 2014-09-25
AU2014236281B2 (en) 2018-03-08
JP6450365B2 (ja) 2019-01-09
JP7227951B2 (ja) 2023-02-22
US20170081382A1 (en) 2017-03-23
CR20200004A (es) 2020-03-11
SMT201900415T1 (it) 2019-09-09
US9580486B2 (en) 2017-02-28
TN2015000416A1 (en) 2017-01-03
BR112015022440A2 (pt) 2017-10-24
CA2906708A1 (en) 2014-09-25
EA034326B1 (ru) 2020-01-28
RS58791B1 (sr) 2019-07-31
TR201908362T4 (tr) 2019-06-21
US20240327485A1 (en) 2024-10-03
US10093711B2 (en) 2018-10-09
MY202248A (en) 2024-04-19
HRP20190970T1 (hr) 2019-07-26
IL241349A0 (en) 2015-11-30
JP2016518823A (ja) 2016-06-30
ES2737598T3 (es) 2020-01-15
AP2015008737A0 (en) 2015-09-30
AU2014236316B2 (en) 2018-11-01
MX372880B (es) 2020-07-08
US9932380B2 (en) 2018-04-03
TWI687435B (zh) 2020-03-11
ME03482B (me) 2020-01-20
MA49207B1 (fr) 2022-08-31
JP2016514161A (ja) 2016-05-19
TW202005979A (zh) 2020-02-01
SG11201507420UA (en) 2015-10-29
TWI709572B (zh) 2020-11-11
KR20150127185A (ko) 2015-11-16
US20180319859A1 (en) 2018-11-08
UY40090A (es) 2023-04-14
US9546203B2 (en) 2017-01-17
KR102219124B1 (ko) 2021-02-22
MA38477B1 (fr) 2019-05-31
UY35454A (es) 2014-09-30
PE20151763A1 (es) 2015-12-10
CA3149348C (en) 2023-09-12
WO2014153111A3 (en) 2014-11-13
SG11201507574VA (en) 2015-10-29
KR20150130342A (ko) 2015-11-23
NZ751148A (en) 2021-05-28
CA2905141A1 (en) 2014-09-25
TR201910802T4 (tr) 2019-08-21
MX366854B (es) 2019-07-26
TW202115106A (zh) 2021-04-16
JO3796B1 (ar) 2021-01-31
SI2970441T1 (sl) 2019-07-31
JP2025066162A (ja) 2025-04-22
LT2970441T (lt) 2019-06-10
CY1121767T1 (el) 2020-07-31
IL241622B (en) 2020-09-30
EA201591731A1 (ru) 2016-04-29
US10829535B2 (en) 2020-11-10
MA49207A1 (fr) 2021-09-30
PH12015502051A1 (en) 2016-01-18
EP2970441A1 (en) 2016-01-20
US20210094997A1 (en) 2021-04-01
US20170137485A1 (en) 2017-05-18
RS58854B1 (sr) 2019-07-31
LT2970423T (lt) 2019-05-27
CN105143253A (zh) 2015-12-09
HRP20191075T1 (hr) 2019-09-20
CL2015002686A1 (es) 2016-04-15
WO2014153111A2 (en) 2014-09-25
AR095541A1 (es) 2015-10-21
EP2970441B1 (en) 2019-03-06
CA2906708C (en) 2022-05-03
CY1121823T1 (el) 2020-07-31
JP2021040630A (ja) 2021-03-18
PT2970423T (pt) 2019-07-23
MY172991A (en) 2019-12-17
US20140343252A1 (en) 2014-11-20
PL2970423T3 (pl) 2019-10-31
PT2970441T (pt) 2019-06-11
PL2970441T3 (pl) 2019-09-30
MX2015012890A (es) 2015-12-03
EA201591766A1 (ru) 2016-02-29
US11976102B2 (en) 2024-05-07
PH12015502051B1 (en) 2016-01-18
TWI784288B (zh) 2022-11-21
US10562950B2 (en) 2020-02-18
CN105143253B (zh) 2021-02-19
KR20250002742A (ko) 2025-01-07
UA119140C2 (uk) 2019-05-10
SMT201900301T1 (it) 2019-07-11
HK1220695A1 (en) 2017-05-12
IL241349B (en) 2018-08-30
US20180237489A1 (en) 2018-08-23
BR112015022440B1 (pt) 2022-08-16
CL2015002669A1 (es) 2016-09-09
KR20220101009A (ko) 2022-07-18
HUE044321T2 (hu) 2019-10-28
JP6480409B2 (ja) 2019-03-13
KR20230157526A (ko) 2023-11-16
TW201522366A (zh) 2015-06-16
DK2970441T3 (da) 2019-06-03
ES2720225T3 (es) 2019-07-18
CN105358570B (zh) 2019-11-12
NZ712066A (en) 2021-05-28
CR20150557A (es) 2015-11-10
DK2970423T3 (da) 2019-07-08
AU2014236316A9 (en) 2018-11-08
EP2970423B1 (en) 2019-04-24
WO2014153063A1 (en) 2014-09-25
JP2023053148A (ja) 2023-04-12
EA032863B1 (ru) 2019-07-31
US20140286898A1 (en) 2014-09-25
BR112015023145A2 (pt) 2017-11-21
MX2015012912A (es) 2015-12-03
EP2970423A2 (en) 2016-01-20
JP2019058182A (ja) 2019-04-18
KR102418771B1 (ko) 2022-07-08
MA38477A1 (fr) 2017-09-29
SI2970423T1 (sl) 2019-08-30
AU2014236316A1 (en) 2015-10-08
EP2970441A4 (en) 2016-11-23

Similar Documents

Publication Publication Date Title
ME03437B (me) Muteini interleukina-2 za ekspanziju t-regulatornih ćelija
HRP20191968T1 (hr) Monoklonska protutijela protiv klaudina-18 za liječenje karcinoma
JP2017512063A5 (me)
HRP20161531T1 (hr) Fc fuzijski proteini koji sadrže nove linkere ili aranžmane
RU2010133938A (ru) Усовершенствованные векторы экспрессии млекопитающих и их применение
IL309260B1 (en) Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced complement binding
JP2015519344A5 (me)
HRP20230590T1 (hr) Novi fuzijski protein specifičan za cd137 i pd-l1
RU2008110050A (ru) СПОСОБ МАССОВОГО ПРОИЗВОДСТВА ОБЛАСТИ Fc ИММУНОГЛОБУЛИНА С УДАЛЕННЫМИ НАЧАЛЬНЫМИ МЕТИОНИНОВЫМИ ОСТАТКАМИ
Xu et al. Elucidation of the binding mode of the carboxyterminal region of peptide YY to the human Y2 receptor
CN104540853A (zh) 含有包含蛋白g的细胞膜外结构域变体的串联型多聚体的蛋白质的捕获剂
KR20110048777A (ko) 항체 불변 영역에 특이적으로 결합하는 융합 단백질, 그의 제조 방법 및 이를 이용한 항체 분리 방법
CN104387473A (zh) 用于非酶切非色谱纯化方法原核表达融合蛋白Prx的类弹性蛋白多肽ELP
CN106589104B (zh) 人源分子伴侣样蛋白及其表达纯化、晶体结构和应用
JP2019518713A5 (me)
RU2018141714A (ru) Слитый белок, содержащий вариант CCL3, и его применение
KR102345011B1 (ko) GroES 융합을 이용한 글루카곤 유사 펩타이드-1 또는 이의 유사체의 생산방법
Zhang et al. Fusion partners as a tool for the expression of difficult proteins in mammalian cells
CN101818134B (zh) ppGalNAc-T20抗原及其多克隆抗体的制备方法
Barak et al. Expression, derivatization, crystallization and experimental phasing of an extracellular segment of the human Robo1 receptor
KR102301138B1 (ko) 옥신토모듈린 생산용 융합태그
Pyo et al. A large-scale purification of recombinant histone H1. 5 from Escherichia coli
CN102558316A (zh) 高稳定性的具抗体结合能力的重组蛋白a及其生产
Zhao et al. Efficient in vitro refolding and characterization of major histocompatibility complex class I-related chain molecules a (MICA) and natural killer group 2 member D (NKG2D) expressed in E. coli
KR20250154428A (ko) 펩티드의 제조 및 정제를 위한 방법 및 조성물